TScan Therapeutics (TCRX) Fundamental Analysis: Revenue, Earnings & Valuation

2.84 / 10

Underperform

Fundamental rating is Underperform. Inventory turnover (103.9) and interest coverage (35.1) are strong, but revenue growth rates (~267%) sit in low‑return quartiles and cost of sales (64%) is high. Overall metrics point to a defensive, challenging financial profile.

Analysis Checks(5/10)

Revenue-MV

Value-1.59

Score1/3

Weight38.31%

1M Return4.09%

Total operating revenue (YoY growth rate %)

Value266.65

Score0/3

Weight-33.19%

1M Return-4.79%

Inventory turnover ratio

Value103.94

Score2/3

Weight-8.80%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value17.69

Score3/3

Weight14.33%

1M Return1.67%

PB-ROE

Value-0.82

Score1/3

Weight62.34%

1M Return7.56%

Long-term debt to working capital ratio (%)

Value0.63

Score3/3

Weight6.75%

1M Return0.87%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-8.94%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value266.65

Score0/3

Weight-32.06%

1M Return-4.63%

Cost of sales ratio (%)

Value64.41

Score2/3

Weight-8.45%

1M Return-1.13%

Asset-MV

Value-0.55

Score1/3

Weight69.70%

1M Return6.31%

Is TCRX fundamentally strong?

TCRX scores 2.84/10 on fundamentals and holds a Premium valuation at present. Backed by its -71.28% ROE, -1256.81% net margin, -0.45 P/E ratio, 0.48 P/B ratio, and 12.28% earnings growth, these metrics solidify its Underperform investment rating.